About Biopharmaceuticals sector in Netherlands
The Biopharmaceuticals sector in Netherlands comprises 190 companies, including 144 funded companies having collectively raised $4.36B in venture capital money and private equity. Out of these, 59 are Series A+ funded.
Biopharmaceuticals sector in Netherlands has seen 22 acquisitions and 5 IPOs. This represents almost 14.2% of all such companies - which is higher than the 5.0% exit rate of tech companies in general.
This sector includes companies engaged in R&D for developing pharmaceuticals for the treatment of various diseases.
Companies developing small molecules or biologics for the treatment of different types of diseases are included in this sector. Traditional Pharmaceutical Products, Generic Drugs are excluded.
Top Biopharmaceuticals Companies in Netherlands
There are 190 Biopharmaceuticals startups in Netherlands which include UniQure, Pharvaris, Leyden Labs, ProQR Therapeutics, Pharming Group. Out of these, 144 startups are funded, with 59 having secured Series A+ funding.
Over the past 10 years, an average of 7 new companies have been launched annually. Notably, several of these startups have been founded by alumni of Harvard University, Cornell University and INSEAD.
Here is the list of top Biopharmaceuticals startups in Netherlands
1. UniQure
Developer of gene-based therapies for patients with genetic or acquired diseases. It has developed adeno-associated virus-based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. It also develops AMT-060, gene therapy for the treatment of hemophilia B; S100A1 for congestive heart failure. Other offerings are AMT-021 gene therapy for acute intermittent porphyria, AMT-110, gene therapy for Sanfilippo B syndrome. It also offers AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease.
Key facts about UniQure
- Founded Year: 1998
- Location: Amsterdam (Netherlands)
- Stage: Public
- Total Funding till date: $111M
- Investors: Foresite Capital, Hercules Capital and 11 Others
- Latest Funding Round: Grant (prize money), Apr 01, 2021, $*****
- Tracxn Score: 70/100 What is this?
- Competitors Rank: 6 of 714 Competitors
2. Pharvaris
Pharvaris is a preclinical stage company developing orally deliverable drugs for hereditary angioedema (HAE). The lead candidate, PHA121 is a bradykinin B2 receptor competitive antagonist & demonstrated activity in bradykinin-mediated disease models. The company is advancing this molecule into IND-enabling studies.
Key facts about Pharvaris
- Founded Year: 2015
- Location: Leiden (Netherlands)
- Stage: Public
- Total Funding till date: $164M
- Investors: Foresite Capital, Kurma Partners and 9 Others
- Latest Funding Round: Series C, Nov 18, 2020, $*****
- Tracxn Score: 64/100 What is this?
- Competitors Rank: 5 of 130 Competitors
3. Leyden Labs
Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa. It develops nasal sprays that stop initial infection, prevent onward transmission, protect broadly against existing and new viruses, and provide universal protection, regardless of an individual’s immune history or comorbidities. The company focuses on harnessing mucosal immunity and broad protection by delivering antibodies directly to the nasal mucosa for immediate anti-viral protection. It develops active substances that target regions that lend themselves to lasting protection against multiple strains and entire virus families.
Key facts about Leyden Labs
- Founded Year: 2020
- Location: Amsterdam (Netherlands)
- Stage: Series B
- Total Funding till date: $257M
- Investors: Google Ventures, Casdin Capital and 10 Others
- Latest Funding Round: Venture Debt, Jun 04, 2025, $*****
- Tracxn Score: 64/100 What is this?
- Competitors Rank: 4 of 357 Competitors
Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders. The company has designed therapeutic candidates to specifically target and repair the defective messenger RNA, (mRNA). Their proprietary technology known as Axiomer involves the use of single-stranded RNA-based oligonucleotides, which act as guide sequences to repair (single nucleotide changes to RNA) the targeted abnormal mRNA. The product pipeline includes QR-110, for Leber’s congenital amaurosis patients, QR-421 for mediated retinitis pigmentosa and Usher syndrome, QR-1123 for retinal mediated retinitis pigmentosa.
Key facts about ProQR Therapeutics
- Founded Year: 2012
- Location: Leiden (Netherlands)
- Stage: Public
- Total Funding till date: $58M
- Investors: Sofinnova Partners, Foresite Capital and 7 Others
- Latest Funding Round: Post IPO, Jul 14, 2020, $*****
- Tracxn Score: 63/100 What is this?
- Competitors Rank: 16 of 669 Competitors
Developer of recombinant protein-based therapeutics for rare diseases. The lead product Ruconest is a recombinant human C1 esterase inhibitor for the treatment of angioedema attacks. Also, have enzyme replacement therapy for Pompe disease, leniolisib for the treatment of APDS, rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and covid-19.
Key facts about Pharming Group
- Founded Year: 1988
- Location: Leiden (Netherlands)
- Stage: Public
- Investors: Deerfield, Orbimed and 6 Others
- Latest Funding Round: Post IPO, Jan 14, 2020, $*****
- Tracxn Score: 62/100 What is this?
- Competitors Rank: 59 of 933 Competitors
Companies founded year-on-year in the Biopharmaceuticals sector in Netherlands
16 Biopharmaceuticals startups in Netherlands were founded in 2017 - this is the most number of startups founded in any year in the last 10 years.
- Total Number of Companies
Year | No. of companies |
|---|---|
2026 | - |
2025 | 1 |
2024 | 5 |
2023 | 3 |
2022 | 8 |
2021 | 9 |
2020 | 14 |
2019 | 14 |
2018 | 9 |
2017 | 16 |
Stage-wise distribution of Biopharmaceuticals sector companies in Netherlands
Out of the total 190 Biopharmaceuticals companies in Netherlands, 144 have secured funding. Among them, 59 have reached Series A or higher, and 41 to Series B or beyond.
Founded - 190
Funded - 144
Series A+ - 59
Series B+ - 41
Series C+ - 31
Company Stage | No. of companies |
|---|---|
Founded | 190 |
Funded | 144 |
Series A+ | 59 |
Series B+ | 41 |
Series C+ | 31 |
Let us walk you through our Sectors and other offerings
Designed with precision for VCs, PE, IBs, Incubators, M&A, Innovation more
Designed with precision for VCs, PE, IBs, Incubators, M&A, Innovation more
Funding Trends in the Biopharmaceuticals sector in Netherlands
Total funding year-on-year in the Biopharmaceuticals sector in Netherlands
The Biopharmaceuticals sector in Netherlands saw a total funding of more than $3.07B in the last 10 years. The most amount of funding was in 2021 at more than $543M.
- Total Funding
Year | Total Funding |
|---|---|
2025 | $448M |
2024 | $195M |
2023 | $336M |
2022 | $235M |
2021 | $543M |
2020 | $520M |
2019 | $199M |
2018 | $234M |
2017 | $265M |
Recent Funding Rounds in Biopharmaceuticals in Netherlands
In the year 2025, till December 2025, Biopharmaceuticals companies in Netherlands have raised $417M in equity funding across 13 rounds.
In the same period last year (i.e. till December 2024), Biopharmaceuticals companies in Netherlands had raised $195M across 12 rounds.
So, 2025 has seen a 113.65% rise in funding in Biopharmaceuticals companies in Netherlands as compared to 2024.
Here are some recent, important funding rounds in Biopharmaceuticals companies in Netherlands:
Company | Round Raised | Amount Raised | Funding Date | Investors |
|---|---|---|---|---|
Series A | 4894 | Dec 18, 2025 | ||
Series A | 8028 | Dec 08, 2025 | and 3 more | |
Series A | 4772 | Nov 18, 2025 | ||
Seed | 2817 | Sep 16, 2025 | ||
Seed | 9136 | Aug 12, 2025 |
Top Investors in Biopharmaceuticals in Netherlands
Forbion is the top investor in Biopharmaceuticals companies in Netherlands based on number of companies invested.
Here are some top investors in Biopharmaceuticals companies in Netherlands:
Investor | Location | Top Portfolio Companies |
|---|---|---|
Naarden (Netherlands) | ||
London (United Kingdom) | ||
Amsterdam (Netherlands) | ||
Amsterdam (Netherlands) | ||
Fort Worth (United States) | - |
M&A activity in Biopharmaceuticals sector in Netherlands
In the year 2025, till December 2025, 2 acquisitions happened in Biopharmaceuticals sector in Netherlands. Last year, in 2024, a total of 1 acquisition happened in Biopharmaceuticals sector in Netherlands.
Here are some recent, important acquisitions in Biopharmaceuticals sector in Netherlands:
Company | Acquisition Type | Acquisition Date | Acquirers |
|---|---|---|---|
Business Acquisition | Dec 12, 2025 | ||
Business Acquisition | Aug 04, 2025 | ||
Business Acquisition | Dec 02, 2024 | ||
Business Acquisition | Oct 02, 2023 | ||
Business Acquisition | Jun 01, 2023 |
Acquisition trends in Biopharmaceuticals sector in Netherlands
Here are the acquisition trends in Biopharmaceuticals sector in Netherlands:
- Total Number of Acquisitions
Year | No. of companies |
|---|---|
2026 | - |
2025 | 2 |
2024 | 1 |
2023 | 3 |
2022 | 2 |
2021 | 1 |
2020 | 2 |
2019 | 1 |
2018 | 1 |
2017 | - |
IPOs in Biopharmaceuticals in Netherlands
In the year 2021, till March 2021, 3 IPOs happened in Biopharmaceuticals sector in Netherlands.
Here are some recent, important IPOs in Biopharmaceuticals sector in Netherlands:
Company | IPO Date | Exchange Symbol |
|---|---|---|
Mar 25, 2021 | National Association of Securities Dealers Automated Quotations (NASDAQ) | |
Feb 08, 2021 | National Association of Securities Dealers Automated Quotations (NASDAQ) | |
Feb 05, 2021 | National Association of Securities Dealers Automated Quotations (NASDAQ) | |
Jun 02, 2016 | National Association of Securities Dealers Automated Quotations (NASDAQ) | |
Jul 02, 2015 | Euronext Exchange (Euronext) |
Colleges which produce the most Biopharmaceuticals companies in Netherlands
Companies founded by alumni from top colleges in the Biopharmaceuticals in Netherlands
Most number of Biopharmaceuticals startups in Netherlands have been founded by alumni from Harvard University, Cornell University and INSEAD.
College | No. of companies |
|---|---|
Harvard University | 2 |
Cornell University | 1 |
INSEAD | 1 |
Kellogg School of Management | 1 |
London School of Economics and Political Science | 1 |
Massachusetts Institute of Technology | 1 |
Stanford University | 1 |
University of California (Berkeley) | 1 |
University of California (Los Angeles) | 1 |
University of Oxford | 1 |
Total funding in Biopharmaceuticals companies founded by alumni from top colleges in Netherlands
In the last 10 years, INSEAD graduates' Biopharmaceuticals companies in Netherlands have raised the most funding among top colleges. University of California (Los Angeles) alumni are second, and Cornell University alumni are third.
College | Total Funding |
|---|---|
INSEAD | $164M |
University of California (Los Angeles) | $103M |
Cornell University | $67.6M |
Kellogg School of Management | $67.6M |
London School of Economics and Political Science | $37.1M |
Harvard University | $2.5M |
University of California (Berkeley) | $1.94M |
Stanford University | $157K |
Massachusetts Institute of Technology | - |
University of Oxford | - |
Top News in Biopharmaceuticals in Netherlands
•
•
•
•
Pharming Group Receives FDA Priority Review for Leniolisib in Children with APDSGlobeNewswire•Oct 01, 2025•Pharming Group
•
•
Kling Bio & Sanofi Collaborate to Discover Neutralizing AntibodiesPR Newswire•Jul 24, 2025•Kling Bio, Sanofi
•
VarmX Receives FDA Approval to Commence Phase 3 Trial for Urgent Surgery TreatmentPharmaTimes•Jul 08, 2025•Varmx
•
ProQR Submits CTA for AX-0810 Phase 1 Study Targeting NTCPGlobeNewswire•Jun 27, 2025•ProQR Therapeutics
•
•
VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical OfficerBusiness Wire•Apr 01, 2025•VectoryTx
